SCP
WVE icon

SymBiosis Capital Partners’s Wave Life Sciences WVE Stock Holding History

SymBiosis Capital Partners’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.44M Buy
+750,000
New +$9.77M 10.3% 3

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
GP
GSK plc London $602M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

SymBiosis Capital Partners's WVE Position: Q1 2026 in Review

SymBiosis Capital Partners opened a new position in Wave Life Sciences (WVE) in Q1 2026: 750,000 shares worth $5.44M. The stake represents 10.3% of the portfolio and ranks #3 among its holdings.

232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • SymBiosis Capital Partners held 750,000 shares of Wave Life Sciences worth $5.44M as of Q1 2026.
  • Wave Life Sciences was a new SymBiosis Capital Partners position in Q1 2026.
  • Wave Life Sciences made up 10.3% of SymBiosis Capital Partners's portfolio in Q1 2026, its #3 holding.
  • 232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.